Epitalon dosage - how to use and what forms are available?

Epitalon dosage is one of the most frequently discussed topics related to this peptide. This is mainly due to the lack of uniform standards and the diverse research models in which it has been analyzed. In scientific literature, Epitalon doses vary depending on the species, route of administration, and research objective. In many cases, very low concentrations were used, suggesting that biological activity can occur even at minimal amounts.

W cell research Effects were observed even at concentrations on the order of 10⁻¹⁷–10⁻¹⁵ M. This suggests a possible mechanism of action based on very low concentrations. In contrast, in vivo studies used higher doses, calculated per body weight or per individual. This clearly shows that the dosing approach for this peptide is varied.

Epithalon Dosage Protocol

Epitalon dosing protocols in scientific research were most often based on cyclical patterns. This means the peptide was administered for a specific period, followed by a break. animal models, such as mice and rats, doses ranging from 0.1 µg to 1 µg per animal were used. They were typically administered several times a week for periods ranging from a few days to many months. In some long-term experiments, Epitalon was administered until the animals' natural death, allowing its effects to be assessed with prolonged exposure.

W Bclinical trials A different approach was used. An example is sublingual administration of 0.5 mg daily for 20 days. This shows an attempt to adapt regimens for human applications. Importantly, the effects did not always increase with increasing doses. In some cases, lower concentrations yielded more pronounced results than higher ones.

Epitalon injection dosage

Epitalon injection dosage is the most commonly described administration method in the literature. animal research Subcutaneous, intramuscular, and in some cases, intraperitoneal administration were used. Typical doses were in the microgram range. For example, 1 µg per mouse was administered five times a week for many months. In other experiments, lower doses, such as 0.1 µg per individual, were used and also led to noticeable biological effects.

In ophthalmological studies, Epitalon was administered topically, for example, subconjunctivally at a dose of approximately 5 µg per application for 10 days. This shows the possibility of local application. The variety of these routes indicates that the injection route was often chosen for better control of the peptide's bioavailability and stability.

What doses Epithalon Were they described in the research?

Published doses of Epithalon vary significantly because studies have used different species, endpoints, routes of administration, and durations of experiments. Described regimens include microgram-level subcutaneous doses in rodents, nanogram-level intranasal doses in rats, and longer, repeated regimens in aging studies. These experimental amounts do not constitute validated human dosage recommendations. [1–7]

The most important issue is that there is no single research dosage that can be defined as the „Epitalon dosage.” Different researchers have used Epithalon to answer various biological questions, and the administered amount was tailored to the specific model.

For example, in a long-term aging study in mice, 1 μg per mouse was administered subcutaneously for five consecutive days each month, starting from the third month of life until natural death. [1] In a related study on female CBA mice, 0.1 μg per animal was administered for five consecutive days each month, starting from the sixth month of life until death. [2]

Other studies used more continuous schedules. Female rats exposed to various lighting conditions received 0.1 μg per rat five times a week, starting from the fourth month of life. [3] A similar gerontological study on male rats also used 0.1 μg per rat subcutaneously five times a week from the fourth month of life until natural death. [4]

Studies in cancer models used still other regimens. In one experiment on colorectal carcinogenesis in rats, 1 μg per rat was administered five times a week for six months in one of the experimental groups. [5]

Intranasal studies used amounts expressed in nanograms, rather than micrograms. An English-language study on the rat neocortex reported 30 ng per animal as a single intranasal exposure, whereas an earlier Russian publication from the same research program reported 2 ng per animal. [6,7] The discrepancy in doses should be preserved rather than artificially standardized, as the publications may concern related but not identical experiments.

These values are best presented as study-specific exposures rather than instructions that can be extrapolated to humans.

What is the Epithalon Dosing Protocol?

The Epithalon dosing protocol is the full experimental scheme used in a study—including the dose, route of administration, frequency, duration of treatment, time of administration, species, and evaluated endpoint—rather than just the number of milligrams per day. Published protocols vary significantly, and available clinical evidence has not established a single, universally validated Epitalon protocol for humans.

The word „protocol” is often used on the internet as if it simply means „how much Epitalon to take.” In scientific research, it means much more.

The research protocol may include the amount administered during a single exposure, whether the substance was administered subcutaneously, intranasally, orally, intramuscularly, or directly to cultured cells, how frequently the exposure occurred, how long the intervention lasted, when measurements were taken, and what biological endpoint was analyzed.

For example, the 2003 aging study on SHR mice was not limited to the use of „1 μg.” It used 1 μg per mouse subcutaneously for five consecutive days each month, starting from the third month of life and continuing until natural death. [1]

Meanwhile, in the lighting study in rats, 0.1 μg per rat was administered five times a week, starting from the fourth month of life, and survival and tumor development were observed throughout the animals' lifespan. [3]

These are fundamentally different protocols, even though subcutaneous administration was used in both cases.

Taken out of the context of the entire protocol, the dose value therefore loses a significant part of its scientific meaning.

What Is the Difference Between Dose, Frequency, and Cycle Length?

Dose, frequency, and cycle length describe different elements of the Epithalon study protocol. Dose refers to the amount administered during a single exposure, frequency specifies how often it is administered, and cycle length denotes the duration of a given treatment period or the number of consecutive days of administration. Published studies have used a wide variety of combinations of all these parameters.

A good example is the monthly regimen in mice. In an experiment using Swiss-bred SHR mice, the dose was 1 μg per mouse, the frequency within the cycle was once daily for five consecutive days, and the cycle was repeated once a month from the third month of life until natural death. [1]

In another study of HER-2/neu transgenic mice, 1 μg was administered subcutaneously for five consecutive days each month, starting from the second month of life. [8]

In contrast, studies on lighting in rats used 0.1 μg per animal five times a week, rather than a short five-day cycle once a month. [3,4]

In an experiment on colorectal carcinogenesis, 1 μg was administered five times a week for six months to one of the study groups. [5]

Therefore, the term „Epitalon protocol” itself may conceal significant differences regarding:

• amounts per single dose,
• number of applications per week,
• whether the treatment was intermittent or continuous,
• total duration,
• genre,
• and the research objective.

For this reason, published animal models should not be reduced to a single human „cycle.”.

What Is the Khavinson Protocol for Epitalon?

There is no single peer-reviewed scientific scheme that can be precisely defined as a universal „Khavinson protocol for Epitalon.” Research associated with Khavinson has used various doses and schedules in mice, rats, monkeys, and in laboratory systems, which is why this term is better understood as an informal name for a group of experimental schemes rather than a single standardized clinical protocol.

The term „Khavinson protocol” is widely used in non-scientific discussions, but the published literature does not present a single, uniform protocol applicable to all studies.

The research conducted by Vladimir Khavinson and his colleagues employed various approaches depending on the biological problem under study.

In mice, one study used 1 μg per mouse for five consecutive days each month. [1] Another used 0.1 μg per animal for five consecutive days each month. [2]

In rats, some aging studies have instead used 0.1 μg per animal five times a week for very long periods. [3,4]

In electrophysiological experiments with intranasal administration, nanogram-level quantities were used as single or short-term investigative exposures. [6,7]

The literature therefore does not justify reducing Khavinson's research on Epitalon to a single fixed number of milligrams, a single number of days, or a universal, repeated „cycle.”.

If a commercial or informal source presents a single diagram as the „original Khavinson protocol,” this claim should be verified in the exact original publication from which it is purportedly derived.

How Did Injection, Oral, and Intranasal Protocols Differ?

Epithalon studies involving injection, oral, and intranasal administration used different species, objectives, and exposure regimens. Injections predominate in aging and tumor studies; oral administration is used primarily in gastrointestinal studies in rodents; and intranasal administration was used primarily in neurophysiological studies and experiments involving pineal stress in rats. These routes are not interchangeable and do not have equivalent validation in humans.

Subcutaneous administration is the most common route described in older gerontological literature. In studies on mice, dosing regimens such as 0.1 or 1 μg per animal for five consecutive days each month were used, while studies on rats often used 0.1 μg per animal five times a week. [1–4]

Oral administration has been studied mainly in rodents. In one study, Epithalon was administered per os for one month to old Wistar rats, analyzing intestinal enzyme activity. The PubMed abstract confirms the route and duration, but does not provide the dose, so it should not be made up for this study. [9]

Intranasal administration has been used in neurophysiological and stress-related studies in rats. In a 2007 experiment on cortical neurons, a single reported dose of 30 ng per animal was used, whereas a related Russian publication from 2006 reports 2 ng. [6,7]

In another study in rats, repeated intranasal administration was used prior to evaluation of the pineal gland tissue, but the abstract in PubMed does not provide sufficient details regarding the dose to allow for a numerical protocol to be presented.

These routes should not be compared as if the same nominal amount leads to the same exposure. Absorption, degradation, tissue distribution, and pharmacokinetics differ depending on the route of administration, and robust comparative pharmacokinetic data in humans are unavailable.

What Daily Dose of Epitalon Was Used in Published Studies?

Published studies have used doses ranging from nanograms in acute intranasal experiments on rats to micrograms per animal in repeated-dose studies on rodents. However, the term „daily” may be misleading, as some regimens were intermittent, monthly, or limited to specific treatment days, rather than involving continuous daily administration. [1–7]

The examples clearly show this range.

In a study of cortical neurons in rats, a single intranasal dose of 30 ng was administered. [6] A related Russian publication reported a dose of 2 ng. [7]

In chronic studies on female rats, 0.1 μg per rat was administered on each treatment day, five days a week. [3]

The memory study in rats also administered 0.1 μg per animal per day, starting from the fourth month of life. [10]

In aging studies in mice, 0.1 μg or 1 μg per mouse was often used on each day of treatment, but usually only for five consecutive days each month, rather than every day throughout the entire month. [1,2]

In the experiment concerning colorectal carcinogenesis, 1 μg per rat was administered on each treatment day, five times a week, in a six-month regimen. [5]

One historical publication concerning HER-2/neu represents an important exception requiring caution: its PubMed abstract lists 1 mg subcutaneously five times a week, whereas closely related HER-2/neu studies list 1 μg. [11] Because this is a thousand-fold discrepancy in very similar experimental literature, the value should be reproduced exactly as published and marked as requiring verification in the full text, rather than assuming it represents the standard regimen.

What does a 10 mg or 50 mg vial mean?

The 10 mg or 50 mg vial designation indicates the nominal total mass of the peptide declared in the container. It does not determine an evidence-based dose, treatment cycle, concentration, purity, number of administrations, or appropriate route of administration, and published Epitalon studies cannot be converted into a protocol based solely on vial size.

A 10 mg vial nominally contains 10 milligrams of the material designated as Epitalon, while a 50 mg vial nominally contains 50 milligrams.

Such a statement describes the contents of the package, not the research design.

It does not inform:

how much should be given,

how often should it be given,

how should the material be prepared,

does the declared mass refer to pure AEDG or does it also include the salt/counterion share?,

has the declared purity been independently verified,

nor whether the material is sterile or suitable for a specific route of administration.

This distinction is particularly important because many published animal studies on Epitalon used microgram-level amounts rather than the milligram amounts typical of commercial vials. [1–5]

Therefore, the size of the vial does not have a direct equivalent in the dose used in the published study.

During quality assessment, the vial should be analyzed separately for identity, purity, analytical documentation, formulation, and intended research context.

Why Doesn't the Dose Calculator Replace the Research Protocol?

The dosage calculator can perform mathematical operations, but it cannot determine whether a dose is biologically appropriate, as Epithalon studies vary by species, route of administration, pharmacokinetics, frequency, duration, formulation, and endpoint. Simple conversion of a mouse or rat dose based on body weight does not replicate the exposure or scientific conditions of the original experiment.

The calculator can answer mathematical questions, such as unit conversion or multiplying quantities by body weight.

It cannot answer pharmacological questions such as:

is the absorption comparable,

does peptide degradation proceed similarly,

is the same concentration achieved in the tissues,

Does the route of administration change bioavailability?,

or whether chronic exposure behaves similarly between species.

For example, in a 2003 study on SHR mice, a dose of 1 μg per mouse was used, which is approximately 30–40 μg/kg. [1] This does not mean that multiplying a human's body weight by 30–40 μg/kg would replicate the mouse experiment.

The schedule in mice was also periodic — five consecutive days a month — and lasted for a significant portion of the animal's life. [1]

Similarly, a 30 ng intranasal dose in the rat was intended to study cortical electrical activity for the subsequent 30 minutes, rather than to investigate aging or clinical efficacy. [6]

Merely converting the numbers thus removes significant experimental differences.

A calculator can reproduce arithmetic, but not translational pharmacology.

Why Research Doses Should Not Be Presented as Medical Advice

Research doses should not be presented as medical advice, because most Epitalon regimens come from animal studies or laboratory experiments, no standard approved human dose has been established for the proposed uses related to anti-aging, sleep, telomeres, or longevity, and translating experimental exposures into self-administration instructions would go beyond the available clinical evidence.

The dose used to test the hypothesis in mice is not automatically a therapeutic dose.

Intranasal exposure in the rat used for recording neuronal activity is not automatically a recommendation for intranasal dosing.

A long-term mouse protocol designed to study mortality and cancer does not automatically translate to the human longevity cycle.

Published literature regarding Epithalon also shows significant variability and sometimes even apparent discrepancies, such as the aforementioned values of 1 mg and 1 μg in the HER-2/neu publications. [8,11]

This uncertainty is one of the reasons why experimental quantities should always remain linked to the specific study in which they were applied.

A clinically useful dosage recommendation would require data on human pharmacokinetics, dose-response relationships, efficacy, adverse effects, contraindications, interactions, safety dependent on the route of administration, and repeated exposure. These data have not been established for Epitalon at the level required for approved therapy.

Therefore, the most appropriate editorial approach is:

„The following quantities describe only published experimental protocols and do not constitute recommended human doses or instructions for self-administration.”

Research Dosage Summary

The table shows the main point: published Epitalon studies cover many different regimens rather than a single validated dosing protocol.

Epithalon vials

Epitalon dosage vials refers to the form of the preparation, which most often occurs as a lyophilized powder. This form is stable and allows for longer storage before preparing the solution. After dissolution, a solution of a specific concentration is obtained, used according to the chosen protocol.

W in laboratory practice The contents of the vials can be a few or a dozen milligrams. However, the actual dose depends on the volume of solvent used and the method of administration. The lyophilization process allows for the preservation of the peptide's structure and enables precise dosing.

Epitalon dissolution

The dissolution process of epitalon is of great importance for the quality of the prepared solution. In laboratory practice, sterile water or bacteriostatic water, which limits microbial growth, is most commonly used.

Dissolving should be gentle, without vigorous shaking. The structure of peptides is sensitive to mechanical factors. Proper preparation of the solution affects the uniformity of concentration and the repeatability of results, which is particularly important in research.

Epitalon dosage in the morning

Epitalon dosage in the morning is analyzed in the context of circadian rhythm and pineal gland function. Epitalon has been shown to be related to melatonin regulation, so the timing of administration may be significant for its effects.

Studies in monkeys and humans have observed time-dependent changes in melatonin and cortisol levels. Particularly in older individuals, normalization of hormonal rhythms was noted. This suggests that the timing of administration may play a significant role.

Epitalon dosage orally / epitalon orally

Epitalon oral dosage was mainly analyzed in rat studies. In one experiment, 100 µg was administered daily for a month. The effect on glucose transport and enzyme activity in the small intestine was observed.

The results indicated an increase in both passive and active transport of nutrients. At the same time, it should be noted that peptides are susceptible to degradation in the gastrointestinal tract. This can limit their bioavailability in this form.

Epitalon capsules

The capsule form, described as epithalon capsules, is less frequently reported in studies. However, it appears as an alternative to injections. Its advantage is its ease of use.

On the other hand, biological stability and efficacy may be lower due to digestive processes. Therefore, this form remains less documented in the context of experimental research.

Transdermal Epitalon

Epitalon transdermal is a direction related to modern methods of peptide delivery. In silico studies have analyzed the use of carriers, such as dendrimers, which can support transport through the skin.

Although experimental data are still limited, the development of transdermal systems may offer an alternative to injections in the future.

How to use Epitalon?

Epitalon usage depends on the chosen form of administration and the intended purpose. Studies have used various routes, including injections, oral administration, and intranasal administration.

In some experiments, intranasal administration has been shown to lead to rapid effects in the nervous system. This may suggest action at the central level. Epitalon usage included both short interventions and long-term regimens, demonstrating the broad scope of research applications.

Epitalon peptide dosage

Epitalon peptide dosage indicates the unique property of this compound, which is its activity at very low concentrations. In many cases, the biological effects did not increase with the dose.

Furthermore, situations were observed where lower concentrations produced stronger effects than higher ones. This nonlinear response character suggests regulatory mechanisms rather than a classical dose-effect relationship.

Summary

This article is for educational, scientific, and informational purposes only and does not constitute medical advice, diagnosis, therapeutic guidance, or a recommendation for use. Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide and is not an FDA- or EMA-approved therapy for the treatment of aging, telomere shortening, sleep disorders, cognitive decline, cancer, or any other conditions discussed herein. Much of the available evidence comes from cell cultures, animal experiments, and other preclinical studies, while controlled clinical data involving humans and long-term safety data remain limited. The experimental doses and routes of administration described above are included solely for the purpose of explaining published research and should not be construed as instructions for self-administration. Anyone making decisions regarding an experimental peptide or their health status should consult a licensed healthcare professional and verify current regulatory information with the appropriate national authority.

References

• Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025 Mar 17;26(6):2691. doi: 10.3390/ijms26062691. PMID: 40141333; PMCID: PMC11943447. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
• [1] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., Zabezhinski, M. A., Alimova, I. N., Rosenfeld, S. V., Zavarzina, N. Y., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. https://doi.org/10.1023/A:1025114230714

  [2] Anisimov, V. N., Khavinson, V. K., Mikhalski, A. I., & Yashin, A. I. (2001). Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mechanisms of Ageing and Development, 122(1), 41–68. https://doi.org/10.1016/S0047-6374(00)00184-6

  [3] Vinogradova, I. A., Bukalev, A. V., Zabezhinski, M. A., Semenchenko, A. V., Khavinson, V. K., & Anisimov, V. N. (2007). Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine, 144(6), 825–830. https://doi.org/10.1007/s10517-007-0441-z

  [4] Vinogradova, I. A., Bukalev, A. V., Zabezhinski, M. A., Semenchenko, A. V., Khavinson, V. K., & Anisimov, V. N. (2008). Geroprotective effect of Ala-Glu-Asp-Gly peptide in male rats exposed to different illumination regimens. Bulletin of Experimental Biology and Medicine, 145(4), 472–477. https://doi.org/10.1007/s10517-008-0121-7

  [5] Kossoy, G., Ben-Hur, H., Popovich, I., Zabezhinski, M., Anisimov, V., Khavinson, V., & Zusman, I. (2003). Epitalon and colon carcinogenesis in rats: Proliferative activity and apoptosis in colon tumors and mucosa. International Journal of Molecular Medicine, 12(4), 473–477. https://pubmed.ncbi.nlm.nih.gov/12964022/

  [6] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nozdrachev, A. D. (2007). Effects of intranasal administration of Epitalon on neuron activity in the rat neocortex. Neuroscience and Behavioral Physiology, 37(9), 889–893. https://doi.org/10.1007/s11055-007-0095-3

  [7] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nosdrachev, A. D. (2006). Intranasal Epitalon infusion modulates neuronal activity in the rat neocortex. Sechenov Physiological Journal of Russia, 92(8), 949–956. https://pubmed.ncbi.nlm.nih.gov/17217245/

  [8] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Provinciali, M., Mancini, R., & Franceschi, C. (2002). Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging. Bulletin of Experimental Biology and Medicine, 133(2), 167–170. https://doi.org/10.1023/A:1015555023692

  [9] Khavinson, V. K., Timofeeva, N. M., Malinin, V. V., Gordova, L. A., & Nikitina, A. A. (2002). Effect of Vilon and Epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats. Bulletin of Experimental Biology and Medicine, 134(6), 562–564. https://pubmed.ncbi.nlm.nih.gov/12660839/

  [10] Vinogradova, I. A. (2006). Comparative study of the effects of melatonin and Epitalon on protracted memory under shuttle-labyrinth test conditions in rats during aging. Experimental and Clinical Pharmacology, 69(6), 13–16. https://pubmed.ncbi.nlm.nih.gov/17209456/

  [11] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Semchenko, A. V., & Yashin, A. I. (2002). Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic HER-2/neu mice. Bulletin of Experimental Biology and Medicine, 134(2), 187–190. https://doi.org/10.1023/A:1021104819170